Wolverine Trading’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $21.3M | Buy |
483,100
+175,100
| +57% | +$8.18M | 0.02% | 566 |
|
|
2025
Q2 | $14.3M | Buy |
+308,000
| New | +$15.1M | 0.01% | 568 |
|
|
2025
Q1 | – | Sell |
-249,100
| Closed | -$14M | – | 4781 |
|
|
2024
Q4 | $14M | Sell |
249,100
-206,400
| -45% | -$11.5M | 0.01% | 626 |
|
|
2024
Q3 | $23.2M | Buy |
455,500
+128,500
| +39% | +$6.03M | 0.02% | 391 |
|
|
2024
Q2 | $13.6M | Buy |
327,000
+82,100
| +34% | +$3.67M | 0.01% | 520 |
|
|
2024
Q1 | $13.3M | Buy |
244,900
+32,800
| +15% | +$1.67M | 0.01% | 550 |
|
|
2023
Q4 | $10.9M | Sell |
212,100
-41,400
| -16% | -$2.17M | 0.01% | 687 |
|
|
2023
Q3 | $14.7M | Sell |
253,500
-16,700
| -6% | -$1.02M | 0.02% | 486 |
|
|
2023
Q2 | $17.3M | Buy |
+270,200
| New | +$18.1M | 0.02% | 394 |
|
|
2022
Q4 | – | Sell |
-441,600
| Closed | -$31.7M | – | 4029 |
|
|
2022
Q3 | $31.7M | Sell |
441,600
-30,200
| -6% | -$2.19M | 0.05% | 206 |
|
|
2022
Q2 | $36.9M | Buy |
471,800
+51,400
| +12% | +$3.91M | 0.06% | 172 |
|
|
2022
Q1 | $31M | Buy |
420,400
+46,500
| +12% | +$3.12M | 0.04% | 308 |
|
|
2021
Q4 | $23.4M | Sell |
373,900
-18,100
| -5% | -$1.06M | 0.03% | 422 |
|
|
2021
Q3 | $23.8M | Buy |
392,000
+54,800
| +16% | +$3.61M | 0.03% | 464 |
|
|
2021
Q2 | $22.3M | Buy |
337,200
+39,200
| +13% | +$2.56M | 0.03% | 377 |
|
|
2021
Q1 | $18.9M | Sell |
298,000
-7,600
| -2% | -$473K | 0.03% | 414 |
|
|
2020
Q4 | $18.9M | Buy |
305,600
+70,900
| +30% | +$4.36M | 0.03% | 417 |
|
|
2020
Q3 | $14.1M | Sell |
234,700
-11,300
| -5% | -$680K | 0.03% | 409 |
|
|
2020
Q2 | $14.2M | Sell |
246,000
-105,600
| -30% | -$6.32M | 0.04% | 343 |
|
|
2020
Q1 | $19.1M | Sell |
351,600
-248,500
| -41% | -$15.2M | 0.06% | 235 |
|
|
2019
Q4 | $38.2M | Buy |
600,100
+193,100
| +47% | +$11.1M | 0.09% | 161 |
|
|
2019
Q3 | $20.4M | Sell |
407,000
-45,500
| -10% | -$2.14M | 0.06% | 278 |
|
|
2019
Q2 | $20.5M | Sell |
452,500
-360,800
| -44% | -$16.8M | 0.06% | 281 |
|
|
2019
Q1 | $38.8M | Buy |
813,300
+398,800
| +96% | +$19.9M | 0.11% | 130 |
|
|
2018
Q4 | $21.1M | Buy |
414,500
+193,800
| +88% | +$10.4M | 0.06% | 243 |
|
|
2018
Q3 | $13.7M | Buy |
220,700
+1,200
| +0.5% | +$71.2K | 0.03% | 430 |
|
|
2018
Q2 | $13.9M | Hold |
219,500
| – | – | 0.03% | 368 |
|
|
2018
Q1 | $13.9M | Sell |
219,500
-113,900
| -34% | -$7.33M | 0.03% | 368 |
|
|
2017
Q4 | $20.4M | Buy |
333,400
+72,500
| +28% | +$4.53M | 0.07% | 225 |
|
|
2017
Q3 | $16.6M | Buy |
260,900
+6,300
| +2% | +$368K | 0.06% | 261 |
|
|
2017
Q2 | $14.2M | Sell |
254,600
-64,300
| -20% | -$3.5M | 0.07% | 276 |
|
|
2017
Q1 | $17.7M | Sell |
318,900
-22,400
| -7% | -$1.23M | 0.1% | 210 |
|
|
2016
Q4 | $19.9M | Sell |
341,300
-300
| -0.1% | -$16.4K | 0.1% | 205 |
|
|
2016
Q3 | $18.4M | Buy |
341,600
+168,900
| +98% | +$10.8M | 0.09% | 244 |
|
|
2016
Q2 | $12.6M | Buy |
+172,700
| New | +$12.2M | 0.07% | 282 |
|
Other funds holding BMY
Wolverine Trading's BMY Position: Q3 2025 in Review
Wolverine Trading increased its Bristol-Myers Squibb (BMY) stake by 205% in Q3 2025, buying an estimated $3.02M and bringing the position to 96,318 shares worth $4.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1510.
Wolverine Trading first reported a position in BMY in Q2 2016 and has held it in 31 quarters since. The position peaked at $11.1M in Q1 2019. 2,267 funds tracked by Wall St. Rank hold BMY as of Q3 2025.
- Wolverine Trading held 96,318 shares of Bristol-Myers Squibb worth $4.25M as of Q3 2025.
- Wolverine Trading bought 64,734 Bristol-Myers Squibb shares in Q3 2025, an estimated $3.02M.
- Bristol-Myers Squibb made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #1510 holding.
- Wolverine Trading first reported a position in Bristol-Myers Squibb in Q2 2016 and has held it in 31 quarters since.
- Wolverine Trading's Bristol-Myers Squibb position peaked at $11.1M in Q1 2019.
- 2,267 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2025.
Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.